News

Daridorexant, an FDA-approved dual orexin receptor antagonist, had a dose-response relationship observed at month 1 on all 4 efficacy end points for all doses tested.

A recent study showed that patients with obstructive sleep apnea experience significant negative impacts on their physical, social, and emotional functioning.

The pulmonologist at Rush Health and immediate past president of the American Academy of Sleep Medicine provided perspective on some of the intriguing changes to sleep medicine and where the field is headed in the coming years.

A recent study showed that obstructive sleep apnea may impact the long-term disruption of the glymphatic system function and the development of neurodegenerative diseases.

Assessing doses of 3 mg doxepin, results revealed non-statistically significant improvements in latency to sleep onset and latency to persistent sleep that were observed across patients above and at or below the median baseline values.

In a clinical cohort study, approximately 89% of patients with obstructive sleep apnea classified as “Probably-normal” or “Likely-normal" in assessment of sleep biomarker-based neurodegenerative disorder risk.

The pediatric neurologist at the University of California, Davis, provided perspective on some of the mechanistic links between sleep and neurodevelopmental disorders. [WATCH TIME: 3 minutes]

A phase 3 trial plans to investigate the efficacy and safety of AD109, a novel oral medication, for treating obstructive sleep apnea in patients who cannot tolerate continuous positive airway pressure therapy.

Regardless of whether patients were treatment-naïve or taking alerting agents, the safety profile of low-sodium oxybate remained true, with treatment-emergent adverse events attributing to less than 4% of study discontinuations.

Overall, most patients reported satisfaction with cognitive behavioral therapy approach, with completion of lessons associated with a decrease in Fatigue Severity Scale.

The FDA approval of the increased maximum daily dose for amifampridine offers clinicians and patients greater flexibility in treatment regimens for the management of Lambert-Eaton myasthenic syndrome.

The sleep medicine specialist at the University of California, San Francisco provided perspective on some of the innovative therapeutic strategies in development for patients with obstructive sleep apnea. [WATCH TIME: 5 minutes]

A recent study demonstrated no significant difference in sleep efficiency between pediatric patients with epilepsy who used self-help strategies for sleep aids and those who did not.

Here's some of what is coming soon to NeurologyLive® this week.

A recent study presented at SLEEP 2024 showed that depression in patients with isolated REM sleep behavior disorder significantly increased the risk of conversion to neurodegenerative diseases.

Those on low-sodium oxybate, regardless of psychiatric comorbidity status, outperformed placebo on a number of outcomes, including Epworth Sleepiness Scale and weekly cataplexy attacks.

A majority of the small cohort of patients with SMA did not need a polysomnogram at 1 year because respiratory pathology was not a concern, attributable to improvements from disease-modifying therapies.

The assistant professor of neurology in the Perelman School of Medicine at University of Pennsylvania talked about her presentation at CMSC 2024 on the complex interactions of immune cells in multiple sclerosis. [WATCH TIME: 6 minutes]

After 5 weeks of open-label treatment, KP1077-treated patients showed mild adverse events that were typical for a central nervous system stimulant.

The professor of neurology at Mayo Clinic talked about how MOG antibody-associated disease can be diagnosed through specific antibody tests, highlighting its distinct clinical and MRI features. [WATCH TIME: 4 minutes]

Test your neurology knowledge with NeurologyLive®'s weekly quiz series, featuring questions on a variety of clinical and historical neurology topics. This week's topic is on amyotrophic lateral sclerosis (ALS).

Study establishes protocols for ublituximab use in breastfeeding patients with MS, enhancing treatment decision-making.

The phase 3 trials are expected to assess the therapeutic potential of frexalimab dosed every 4 weeks in both patients with relapsing MS and non-relapsing secondary progressive MS.

Known for his expertise in stem cell transplantation, Cleveland Clinic researcher Jeffrey Cohen, MD, shifted gears to discuss other cell-based therapies in his Whitaker Lecture at the CMSC Annual Meeting.

Neurology News Network for the week ending June 1, 2024. [WATCH TIME: 4 minutes]

CMSC speakers discussed how AI technologies, for better or worse, are beginning to shape the management of MS.

Host Jeffrey Wilken, PhD, chats with Marijean Buhse, PhD, RN, NP-C, MSCN; Amy Sullivan, PsyD, ABPP; and John DeLuca, PhD, ABPP, FACRM, FAPA, FAPS, FNAN, about the third day of the 2024 CMSC Annual Meeting in Nashville, Tennessee.

The professor of psychiatry at the University of Toronto discussed the various medications for multiple sclerosis fatigue that have been tested but ultimately fail to outperform placebo. [WATCH TIME: 4 minutes]

Take 5 minutes to catch up on NeurologyLive®'s highlights from the week ending May 31, 2024.

The professor of neurology in the department of medicine, surgery, and neuroscience at the University of Siena, gave perspective on an analysis of the MAGNIFY-MS study, in which treatment with cladribine demonstrated impacts on CNS-related pathology in MS. [WATCH TIME: 4 minutes]